focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,782.50
Bid: 1,782.00
Ask: 1,782.50
Change: -30.00 (-1.66%)
Spread: 0.50 (0.028%)
Open: 1,792.50
High: 1,802.00
Low: 1,782.50
Prev. Close: 1,812.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET COMMENT: UK Stocks To Open Slightly Higher With M&A In Focus

Tue, 22nd Apr 2014 06:41

LONDON (Alliance News) - UK stocks are set to open marginally higher Tuesday, as European markets play catch-up with Wall Street, which made gains over the long Easter weekend despite ongoing tensions in Ukraine.

Spreadbetters are indicating that the FTSE 100 will open slightly higher Tuesday, after closing on Thursday at 6,625.25 points, with CMC markets calling the index up by 28 points, and Alpari UK calling for a jump of 26 points.

US markets posted solid gains on Monday, with the S&P 500 closing up 0.3% and the DJIA closing up 0.4%, as markets appeared to shrug off the breakdown of the deal reached in Geneva for ending the ongoing crisis in Ukraine.

Russian Foreign Minister Sergei Lavrov on Monday accused Ukrainian authorities of violating the recent accord. Lavrov told reporters in Moscow that the government in Kiev has not acted to disarm illegal militants, especially the ones belonging to ultra-nationalist Right Sector.

Lavrov's remarks came a day after at least three people were killed in a shooting incident at a checkpoint manned by pro-Russian separatists near Sloviansk in eastern Ukraine.

"As long as the situation in Ukraine manages to stay contained to the occasional fire fight then market attention is likely to be more focussed on the latest company earnings reports from both side of the Atlantic," said CMC Markets chief market analyst Michael Hewson.

Tuesday's economic and corporate calendars allow a fairly quiet return from the long weekend for UK investors. But amid continued concern over stretched stock valuations, particularly in the technology sector, results due on Wednesday in the US from both Apple and Facebook are likely to be of particular market interest. Equally, in the UK on Wednesday, first quarter numbers from ARM Holdings, chip maker and supplier to Apple, will be closely watched.

Merger and acquisition activity is in focus, amid reports that US pharmaceutical giant Pfizer Inc. offered to acquire rival UK drugmaker AstraZeneca PLC for USD101 billion. The Sunday Times reported the takeover news, citing senior investment bankers and industry sources. While the offer has reportedly been rejected, the market is now anticipating an increased offer from Pfizer.

GlaxoSmithKline said Tuesday that it has signed a three-part inter-conditional transaction with Novartis AG which will see it sell off its Oncology portfolio, acquire Novartis' global Vaccines business, and create a dually-offered Consumer Healthcare business. The series of transactions by the pharmaceutical giant are said to be valued at more than USD25 billion.

The UK banks may also be in focus following a weekend report in the Financial Times that Barclays is set to wind down large parts of its commodity trading business, due to lower revenues and increased scrutiny from regulators.

In a fairly light economic calendar Tuesday, the eurozone consumer confidence survey at 1400 GMT is likely to be the highlight. Ahead of that, eurozone construction output data is due at 0900 GMT, and afterwards, US existing home sales data is due at 1400 GMT. There is no UK data scheduled.

By Jon Darby; jondarby@alliancenews.com; @jondarby100

Copyright © 2014 Alliance News Limited. All Rights Reserved.

More News
25 Sep 2023 08:37

TOP NEWS: GSK's Arexvy vaccine approved for adults over 60 in Japan

(Alliance News) - GSK PLC on Monday said the Japan Ministry of Health, Labour & Welfare has approved Arexvy for adults over 60.

Read more
25 Sep 2023 07:28

GSK's RSV vaccine gets approval in Japan

(Sharecast News) - GSK announced on Monday that its vaccine, Arexvy, has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for preventing respiratory syncytial virus (RSV) disease in adults aged 60 and over.

Read more
19 Sep 2023 09:30

GSK says new HIV PrEP medication authorised by European Commission

(Alliance News) - GSK PLC on Tuesday said the European Commission has authorised ViiV Healthcare's "superior" drug Apretude to reduce the risk of sexually acquired HIV-1 infection.

Read more
18 Sep 2023 09:40

LONDON BROKER RATINGS: Jefferies likes Energean; JPMorgan raises IDS

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
18 Sep 2023 07:57

LONDON BRIEFING: Phoenix Group hails "impressive" first-half

(Alliance News) - Stocks in London are called lower on Monday, as investors focus on the week's upcoming central bank decisions.

Read more
18 Sep 2023 07:18

US FDA approves GSK treatment for myelofibrosis

(Sharecast News) - GSK announced on Monday that the US Food and Drug Administration (FDA) has granted approval for 'Ojjaara', or momelotinib, as a treatment for adults suffering from intermediate or high-risk myelofibrosis with anaemia, including cases of primary myelofibrosis or secondary myelofibrosis.

Read more
15 Sep 2023 21:52

GSK's Ojjaara approved in US for myelofibrosis patients with anaemia

(Alliance News) - GSK PLC on Friday said Ojjaara, also known as momelotinib, has been approved in the US and the "first and only" treatment indicated for myelofibrosis patients with anaemia.

Read more
11 Sep 2023 08:24

Japan accepts GSK's regulatory filing for momelotinib for blood cancer

(Alliance News) - GSK PLC on Monday reported regulatory progress for momelotinib, as Japan's Ministry of Health, Labour & Welfare accepted a review for the blood cancer-focused drug.

Read more
11 Sep 2023 07:54

LONDON BRIEFING: Restaurant Group sells Frankie & Benny's and Chiquito

(Alliance News) - Stocks in London are called higher on Monday, ahead of a busy week of interest rate decisions and economic data.

Read more
6 Sep 2023 09:32

LONDON BROKER RATINGS: Shore says 'buy' B&M; Peel Hunt likes Halfords

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:

Read more
4 Sep 2023 06:00

More UK babies to need hospital treatment over delay of GSK's RSV jab

(Alliance News) - The nation's top children's doctor has warned a delay on a new vaccine to combat respiratory syncytial virus, or RSV, will mean more babies and infants will need hospital treatment this winter.

Read more
1 Sep 2023 09:11

GSK antibody accepted for Japan review, Goldman Sachs reduces stake

(Alliance News) - GSK PLC on Friday said a new drug application for its monoclonal antibody mepolizumab has been accepted for review by the Japanese government.

Read more
1 Sep 2023 07:49

LONDON BRIEFING: Stocks seen higher; UK house prices continue to fall

(Alliance News) - Stocks in London are set to open higher on Friday as markets looked ahead to a data-heavy day.

Read more
1 Sep 2023 07:12

Japan considering GSK's Nucala drug for sinusitis treatment

(Sharecast News) - Japanese regulators are reviewing a new drug application for GSK's Nucala treatment to be used for the treatment of form of adult sinusitis, the biopharma giant announced on Friday.

Read more
23 Aug 2023 12:10

LONDON MARKET MIDDAY: Stocks rise but pound slumps on sub-par UK data

(Alliance News) - Stocks in Europe were on the up heading into Wednesday afternoon, with equity markets in a confident mood on the eve of the Jackson Hole central banking event, shaking off tepid economic data which hurt the pound and euro.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.